Quick Comparison
| Hydroquinone | Kojic Acid | |
|---|---|---|
| Typical Concentration | OTC (where available): 2%. Prescription: 4%. Apply to dark spots only (not entire face) once or twice daily. Use in 3-4 month cycles with 2-3 month breaks. Always use with sunscreen (SPF 30+) — without it, hydroquinone is ineffective. | Concentrations: 1-4%. Kojic dipalmitate is a more stable ester form but less potent. Apply once or twice daily. Often combined with other brightening agents (arbutin, vitamin C, niacinamide). Results visible at 4-8 weeks. |
| Application | Topical (cream, gel, serum). Apply precisely to hyperpigmented areas. Avoid contact with normal skin. | Topical (serum, cream). Store in airtight, opaque packaging. Discard if the product turns brown. |
| Research Papers | 9 papers | 10 papers |
| Categories |
Mechanism of Action
Hydroquinone
Hydroquinone inhibits tyrosinase through multiple mechanisms: competitive alternative substrate, oxidation to semiquinone radicals generating ROS that damage melanocyte mitochondria and ER, copper chelation at tyrosinase active site. Inhibits RNA/DNA synthesis via ribonucleotide reductase interference. Causes melanosome degradation through membrane disruption. Dramatic melanin reduction — eumelanin and pheomelanin pathways suppressed. Selectively affects hyperactive melanocytes, sparing quiescent ones. Fades pigmentation without permanently altering baseline skin color. Pigmentation returns when treatment stops (melanocyte stem cells intact). Enhanced with retinoids (penetration) and sunscreen (prevents UV rebound).
Kojic Acid
Kojic acid (5-hydroxy-2-hydroxymethyl-4H-pyran-4-one) inhibits tyrosinase through copper chelation—tyrosinase is a type-3 copper enzyme requiring two copper ions to catalyze tyrosine to L-DOPA and L-DOPA to dopaquinone. By sequestering copper, kojic acid renders tyrosinase inactive. May also inhibit tyrosinase-related protein-1 (TRP-1). Exhibits direct antioxidant activity, scavenging superoxide and hydroxyl radicals. Relatively unstable—oxidizes with air and light, forming brown degradation products that lose activity; opaque, airtight packaging and low pH improve stability. Kojic dipalmitate is a more stable ester but requires enzymatic cleavage, reducing potency. Contact sensitization can develop with prolonged use.
Risks & Safety
Hydroquinone
Common
Mild redness, stinging, dryness.
Serious
Exogenous ochronosis (paradoxical blue-grey darkening) with prolonged use >6 months, particularly in darker skin tones. Irritant and allergic contact dermatitis.
Rare
Nail discoloration, peripheral neuropathy (extremely rare, systemic exposure).
Kojic Acid
Common
Contact sensitization (developing an allergy over time with repeated use), redness, irritation.
Serious
Contact dermatitis in sensitized individuals.
Rare
Paradoxical darkening in very sensitive skin types.
Full Profiles
Hydroquinone →
The most potent topical depigmenting agent available and the gold standard prescription treatment for melasma and stubborn hyperpigmentation. Hydroquinone inhibits tyrosinase more strongly than any OTC alternative. However, it carries risks with long-term use (ochronosis — paradoxical darkening) and is restricted or banned in many countries. Best used in cycles of 3-4 months under dermatologist guidance.
Kojic Acid →
A natural brightening agent produced as a byproduct of sake and soy sauce fermentation. Kojic acid inhibits tyrosinase by chelating copper, which is required for the enzyme's active site. It is one of the most effective OTC alternatives to hydroquinone for treating hyperpigmentation, melasma, and age spots, though it is less stable in formulation and can cause contact sensitization over time.